LAPATINIB DITOSYLATE (lapatinib) by Teva is 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both epidermal growth factor receptor (egfr [erbb1]) and of human epidermal receptor type 2 (her2 [erbb2]) receptors (estimated ki values of 3nm and 13nm, respectively) with a dissociation half-life of greater than or equal to 300 minutes. Approved for combination with: () capecitabine for the treatment of patients with advanced, metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (her2), including an anthracycline and 3 more indications. First approved in 2024.
Drug data last refreshed 21h ago
4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Ki values of 3nM and 13nM, respectively) with a dissociation half-life of greater…
Worked on LAPATINIB DITOSYLATE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Lapatinib Plus Trametinib in KRAS Mutant NSCLC
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer